Scpharmaceuticals Inc Cash Flow Conversion Efficiency
Scpharmaceuticals Inc cash flow conversion efficiency. Based on the latest financial reports, Scpharmaceuticals Inc (SCPH) has a cash flow conversion efficiency ratio of 0.756x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.11 Million) by net assets ($-21.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Scpharmaceuticals Inc (2015–2024)
Cash flow conversion efficiency of Scpharmaceuticals Inc from 2015 to 2024. This chart illustrates how Scpharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View latest Scpharmaceuticals Inc stock price today for real-time trading data and today's change.
Scpharmaceuticals Inc Cash Flow Conversion Ratio Explained
Scpharmaceuticals Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Scpharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Scpharmaceuticals Inc ranked by their cash flow conversion efficiency. Also see Scpharmaceuticals Inc stock valuation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Rimini Street Inc
NASDAQ:RMNI
|
-0.906x |
|
Jiangmen Kanhoo Industry Co Ltd
SHE:300340
|
-1.328x |
|
Hainan Huluwa Pharmaceutical Group Co Ltd
SHG:605199
|
0.103x |
|
PETROTAL CORP.
F:SER1
|
0.036x |
|
TTS (TRANSPORT TRADE SERVICES)
RO:TTS
|
0.033x |
|
Neuberger Berman IMF Inc
NYSE MKT:NBH
|
-0.035x |
|
Value Line Inc
NASDAQ:VALU
|
0.049x |
|
Arad Investment & Industrial Development Ltd
TA:ARAD
|
0.124x |
Annual Cash Flow Conversion Efficiency for Scpharmaceuticals Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Scpharmaceuticals Inc from 2015 to 2024. Review financial agility of Scpharmaceuticals Inc to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $13.32 Million | $-70.54 Million | -5.296x | -232.68% |
| 2023-12-31 | $37.22 Million | $-59.24 Million | -1.592x | -233.46% |
| 2022-12-31 | $72.43 Million | $-34.58 Million | -0.477x | +0.72% |
| 2021-12-31 | $56.47 Million | $-27.15 Million | -0.481x | -42.66% |
| 2020-12-31 | $82.17 Million | $-27.69 Million | -0.337x | +43.13% |
| 2019-12-31 | $51.37 Million | $-30.44 Million | -0.593x | -61.98% |
| 2018-12-31 | $78.74 Million | $-28.81 Million | -0.366x | -70.99% |
| 2017-12-31 | $106.00 Million | $-22.68 Million | -0.214x | -151.33% |
| 2016-12-31 | $-37.07 Million | $-15.46 Million | 0.417x | -21.12% |
| 2015-12-31 | $-18.24 Million | $-9.64 Million | 0.529x | -- |
About Scpharmaceuticals Inc
scPharmaceuticals Inc., a pharmaceutical company, focuses on developing and commercializing products to optimize the delivery of infused therapies and patient care. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for the treatment of congestion due to fluid overload in adults with chronic heart failure and … Read more